Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes ( SURPASS J‐mono substudy)
Authors' conclusion
Compared with dulaglutide, tirzepatide showed greater potential for normalizing metabolic factors after a standardized meal. Tirzepatide reduced body weight and body fat mass.
Study context
- Population
- Japanese patients with T2D; mean (SD) age 58.6 (7.5) years, diabetes duration 6.0 (6.3) years, BMI 27.5 (3.5) kg/m², baseline HbA1c 66 mmol/mol (8.22%)of 636 in SURPASS J-mono
- Participants
- 48 patients
- Comparison
- Tirzepatide 5, 10 or 15 mg vs dulaglutide 0.75 mg
- Tirzepatide 5 mgn = 9
- Tirzepatide 10 mgn = 11
- Tirzepatide 15 mgn = 9
- Dulaglutide 0.75 mgn = 19reference
Methodological details52-week, multicentre, double-blind, parallel, active-controlled, phase 3, Japan
- 52-week
- Multicentre
- Double-blind
- Parallel
- Active-controlled
- Phase 3
- Japan
Primary result
As reported in the abstract
Change from baseline in AUC 0–6 h after standardized meal test for glucose, insulin, glucagon, C-peptide and TG · Week 32
- Statistically significant differences vs dulaglutide in all tirzepatide arms for glucose, insulin, glucagon, C-peptide and TG, except TG at 10 mg
Further findings
Body composition (bioelectrical impedance) · Week 52
- Tirzepatide 10 mg and 15 mg: significant reduction in body weight
- All tirzepatide doses: significant reduction in body fat mass
Original publication
Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes ( SURPASS J‐mono substudy). Diabetes Obes Metab. Published 2 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →